{"id":56284,"date":"2026-02-04T22:46:14","date_gmt":"2026-02-04T14:46:14","guid":{"rendered":"https:\/\/flcube.com\/?p=56284"},"modified":"2026-02-04T22:46:16","modified_gmt":"2026-02-04T14:46:16","slug":"united-laboratories-ubt251-gets-nmpa-nod-for-sleep-apnea-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56284","title":{"rendered":"United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial"},"content":{"rendered":"\n<p><strong>United Laboratories International Holdings Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3933:HKG\">HKG:\u202f3933<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved a clinical study for its <strong>Category\u202f1 drug candidate UBT251<\/strong> to treat <strong>moderate\u2011to\u2011severe obstructive sleep apnea (OSA)<\/strong> comorbid with obesity. The long\u2011acting <strong>GLP\u20111\/GIP\/GCG triple agonist<\/strong>, already in Phase\u202fII trials for obesity, type\u202f2 diabetes, MASH, and chronic kidney disease, positions United Labs to address a critical unmet need in sleep\u2011disordered breathing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-strategic-deal\">Regulatory Milestone &amp; Strategic Deal<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>United Laboratories International Holdings Ltd (HKG:\u202f3933)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>UBT251 (GLP\u20111\/GIP\/GCG triple agonist)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Moderate\u2011to\u2011severe OSA with obesity<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA Phase\u202fI\/II clinical study approved<\/td><\/tr><tr><td><strong>Existing Approvals<\/strong><\/td><td>Phase\u202fII for overweight\/obesity, T2D, MASH, CKD (China)<\/td><\/tr><tr><td><strong>Global Licensing Deal<\/strong><\/td><td>USD\u202f2\u202fbillion with Novo Nordisk (March\u202f2025)<\/td><\/tr><tr><td><strong>Territory Retained<\/strong><\/td><td>China mainland, Hong Kong, Macau, Taiwan<\/td><\/tr><tr><td><strong>Territory Licensed<\/strong><\/td><td>Global ex\u2011China rights to Novo Nordisk<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Triple Agonist:<\/strong> Chemically synthesized peptide activating <strong>GLP\u20111, GIP, and glucagon receptors<\/strong> to drive weight loss and metabolic improvements<\/li>\n\n\n\n<li><strong>OSA Rationale:<\/strong> Weight reduction reduces airway obstruction; triple agonist mechanism may provide superior efficacy vs. GLP\u20111 alone<\/li>\n\n\n\n<li><strong>Market Need:<\/strong> <strong>100\u2011150\u202fmillion<\/strong> adults in China have OSA; <strong>50%<\/strong> are obese; no approved pharmacotherapy addresses both conditions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>OSA Market Opportunity:<\/strong> China OSA therapeutics market valued at <strong>\u00a515\u202fbillion<\/strong> : (~US$2.1\u202fbillion) in 2025; pharmacotherapy segment growing at <strong>20% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Novo Partnership Validation:<\/strong> $2\u202fB deal underscores global potential; United Labs retains high\u2011value China rights for all indications<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a53\u20135\u202fbillion<\/strong> : (US$420\u2013700\u202fmillion) peak China sales for UBT251 across obesity\/OSA\/T2D indications by 2030<\/li>\n\n\n\n<li><strong>Clinical Timeline:<\/strong> Phase\u202fI\/II OSA trial initiation expected <strong>Q2\u202f2026<\/strong>; data readout could support <strong>global Phase\u202fIII<\/strong> under Novo\u2019s leadership<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Positions United Labs as a leader in metabolic\u2011respiratory comorbidities; validates triple agonist platform beyond diabetes<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and revenue projections for UBT251. Actual results may differ due to clinical trial outcomes, competitive dynamics, and NMPA review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020302119_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026020302119_c.\"><\/object><a id=\"wp-block-file--media-3fff0000-7441-48e5-9814-90e11167faae\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020302119_c.pdf\">2026020302119_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020302119_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3fff0000-7441-48e5-9814-90e11167faae\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>United Laboratories International Holdings Ltd (HKG:\u202f3933) announced that the National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1260,4361,790],"class_list":["post-56284","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-3933","tag-hot-targets","tag-united-laboratories"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"United Laboratories International Holdings Ltd (HKG:\u202f3933) announced that the National Medical Products Administration (NMPA) has approved a clinical study for its Category\u202f1 drug candidate UBT251 to treat moderate\u2011to\u2011severe obstructive sleep apnea (OSA) comorbid with obesity. The long\u2011acting GLP\u20111\/GIP\/GCG triple agonist, already in Phase\u202fII trials for obesity, type\u202f2 diabetes, MASH, and chronic kidney disease, positions United Labs to address a critical unmet need in sleep\u2011disordered breathing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56284\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial\" \/>\n<meta property=\"og:description\" content=\"United Laboratories International Holdings Ltd (HKG:\u202f3933) announced that the National Medical Products Administration (NMPA) has approved a clinical study for its Category\u202f1 drug candidate UBT251 to treat moderate\u2011to\u2011severe obstructive sleep apnea (OSA) comorbid with obesity. The long\u2011acting GLP\u20111\/GIP\/GCG triple agonist, already in Phase\u202fII trials for obesity, type\u202f2 diabetes, MASH, and chronic kidney disease, positions United Labs to address a critical unmet need in sleep\u2011disordered breathing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56284\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T14:46:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-04T14:46:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56284#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56284\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial\",\"datePublished\":\"2026-02-04T14:46:14+00:00\",\"dateModified\":\"2026-02-04T14:46:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56284\"},\"wordCount\":353,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 3933\",\"Hot targets\",\"United Laboratories\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56284#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56284\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56284\",\"name\":\"United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-04T14:46:14+00:00\",\"dateModified\":\"2026-02-04T14:46:16+00:00\",\"description\":\"United Laboratories International Holdings Ltd (HKG:\u202f3933) announced that the National Medical Products Administration (NMPA) has approved a clinical study for its Category\u202f1 drug candidate UBT251 to treat moderate\u2011to\u2011severe obstructive sleep apnea (OSA) comorbid with obesity. The long\u2011acting GLP\u20111\\\/GIP\\\/GCG triple agonist, already in Phase\u202fII trials for obesity, type\u202f2 diabetes, MASH, and chronic kidney disease, positions United Labs to address a critical unmet need in sleep\u2011disordered breathing.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56284#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56284\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56284#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial - Insight, China&#039;s Pharmaceutical Industry","description":"United Laboratories International Holdings Ltd (HKG:\u202f3933) announced that the National Medical Products Administration (NMPA) has approved a clinical study for its Category\u202f1 drug candidate UBT251 to treat moderate\u2011to\u2011severe obstructive sleep apnea (OSA) comorbid with obesity. The long\u2011acting GLP\u20111\/GIP\/GCG triple agonist, already in Phase\u202fII trials for obesity, type\u202f2 diabetes, MASH, and chronic kidney disease, positions United Labs to address a critical unmet need in sleep\u2011disordered breathing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56284","og_locale":"en_US","og_type":"article","og_title":"United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial","og_description":"United Laboratories International Holdings Ltd (HKG:\u202f3933) announced that the National Medical Products Administration (NMPA) has approved a clinical study for its Category\u202f1 drug candidate UBT251 to treat moderate\u2011to\u2011severe obstructive sleep apnea (OSA) comorbid with obesity. The long\u2011acting GLP\u20111\/GIP\/GCG triple agonist, already in Phase\u202fII trials for obesity, type\u202f2 diabetes, MASH, and chronic kidney disease, positions United Labs to address a critical unmet need in sleep\u2011disordered breathing.","og_url":"https:\/\/flcube.com\/?p=56284","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-04T14:46:14+00:00","article_modified_time":"2026-02-04T14:46:16+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56284#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56284"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial","datePublished":"2026-02-04T14:46:14+00:00","dateModified":"2026-02-04T14:46:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56284"},"wordCount":353,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 3933","Hot targets","United Laboratories"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56284#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56284","url":"https:\/\/flcube.com\/?p=56284","name":"United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-04T14:46:14+00:00","dateModified":"2026-02-04T14:46:16+00:00","description":"United Laboratories International Holdings Ltd (HKG:\u202f3933) announced that the National Medical Products Administration (NMPA) has approved a clinical study for its Category\u202f1 drug candidate UBT251 to treat moderate\u2011to\u2011severe obstructive sleep apnea (OSA) comorbid with obesity. The long\u2011acting GLP\u20111\/GIP\/GCG triple agonist, already in Phase\u202fII trials for obesity, type\u202f2 diabetes, MASH, and chronic kidney disease, positions United Labs to address a critical unmet need in sleep\u2011disordered breathing.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56284#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56284"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56284#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56284"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56284\/revisions"}],"predecessor-version":[{"id":56287,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56284\/revisions\/56287"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}